PT -期刊文章盟阿德里安·l·Rabinowicz盟-爱德华Faught AU -大卫·f·库克AU -恩里克Carrazana TI -探索的影响需要一个剂量的救助治疗癫痫发作对医疗利用率(1763)DP - 2021年4月13日TA -神经病学PG - 1763 VI - 96 IP - 15补充4099 - //www.ez-admanager.com/content/96/15_Supplement/1763.short 4100 - //www.ez-admanager.com/conten首页t/96/15_Supplement/1763.full所以Neurology2021 4月13;96 AB -目的:癫痫发作的比例要求第二次救援药物的剂量和那些第二剂量对医疗的影响利用率报告。背景:癫痫集群可能会持续24小时。通过门诊救助治疗有不同的配置文件,可能会影响多个方面的医疗利用率。设计/方法:3大,长期研究的批准seizure-cluster治疗(即直肠安定,鼻内咪达唑仑,安定喷鼻剂),集的比例控制的初始剂量与那些需要第二个剂量之前6或12小时。第二剂量后住院数据收集。结果:直肠安定发作控制≤12小时治疗后,77%的政府(1215/1578)阻止进一步发作(第二剂量没有报告)。对鼻内咪达唑仑、测量控制癫痫治疗后10分钟到6小时,55.5%(1108/1998)的seizure-cluster事件被成功治愈;第二剂量没有管理61.4%的癫痫发作(1226/1998)。安定鼻喷雾剂,没有第二次注射94.5%(3829/4053)的癫痫发作在6小时内初始剂量的12小时内,92.2% (3735/4053)。安定直肠凝胶,16 363年没收集群随后在急诊室治疗。对鼻内咪达唑仑,4患者1严重不良事件(SAE)可能治疗相关的(与第二不报道)。 For diazepam nasal spray, no SAEs were considered treatment related; 3 SAEs occurred the day of/day after a second dose. None required a dose change; all resolved.Conclusions: Across these noncomparative open-label studies, need for a second dose ranged from <10% to <40% at 6 and 12 hours. Differences among approved therapies appear to have the potential to impact healthcare burden and should be considered when selecting rescue therapy for seizure clusters.Disclosure: Adrian Rabinowicz has nothing to disclose. Dr. Faught has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Faught has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SK Life Science. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sage. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for McCaffrey Law Firm. The institution of Dr. Faught has received research support from UCB Pharma. The institution of Dr. Faught has received research support from UCB Pharma. The institution of Dr. Faught has received research support from NINDS. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as a Scientific Review Board Member with CDC. Dave Cook has received personal compensation for serving as an employee of Neurelis, Inc. Dave Cook has received stock or an ownership interest from Neurelis, Inc. Enrique Carrazana has received personal compensation for serving as an employee of Neurelis. Enrique Carrazana has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Neurelis, Alexza, Zogenix, Praxis, Adamas, Avekshan, . Enrique Carrazana has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Marinus, Hawaii-Biotech. Enrique Carrazana has received stock or an ownership interest from Neurelis, Marinus, .